

Mikkel Bring Christensen  
MD PhD, Ledende overlæge  
Department of Clinical Pharmacology  
Center for Translational Research  
**Type of address: Postal address.**  
Denmark  
**Email:** mikkel.bring.christensen@regionh.dk  
**Email:** Mikkel.Bring.Christensen@regionh.dk  
**Phone:** 38635593



## Education

2004: Master of Medicine, University of Copenhagen, Denmark and authorization as a physician; 2006: Permission to practice independently as a physician (full registration); 2013: Specialist in Clinical Pharmacology (aut. ID: 05HN6), The Danish National Board of Health; 2014: PhD in health science (Thesis ISBN: 978-87-92613-44-8), University of Copenhagen; 2016: Leadership Programme (6 modules, 14 days), Capital Region of Denmark; 2021: Research Management Course (6 modules, 9½ days), CBS Executive Fonden.

## Employment History

2004: Resident, Department of Internal Medicine, Koege Hospital, University of Copenhagen, Denmark; 2004-2005: Resident, Department of Orthopedic Surgery, Koege Hospital, University of Copenhagen, Denmark; 2005-2005: GP resident, Solroed Strand, Denmark; 2006-2007: Several short term GP resident positions, Various places in Norway; 2006-2007: Resident physician, Department of Internal Medicine F, Gentofte Hospital University of Copenhagen, Denmark; 2007-2008: Resident physician, Department of Internal Medicine, Amager Hospital University of Copenhagen, Denmark; 2007-2008: Physician, Senior Resident, Department of Clinical Pharmacology, Bispebjerg Hospital, University of Copenhagen, Denmark; 2008-2016: Medical Expert in authorization of medicinal products (10 hours weekly), Danish Medicines Agency; 2009-2010: Clinical Research Assistant, Center for Diabetes Research, Gentofte University Hospital; 2010: Physician, Senior Resident, Department of Hematology, Rigshospitalet, University of Copenhagen, Denmark; 2010-2012: Clinical Research Assistant, Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Denmark; 2012-2013: Physician, Senior Resident, Department of Clinical Pharmacology, Bispebjerg Hospital; 2013-2013: Physician, Senior Resident, Department of Internal Medicine, Gentofte Hospital; 2013-present: Chief Physician, Head of Education, Department of Clinical Pharmacology, Bispebjerg Hospital; 2013-present: Clinical Associate Professor, University of Copenhagen and Bispebjerg Hospital; 2018-present: Postgraduate Associate Professor, Eastern Region of Denmark & University of Copenhagen; 2020-present: Head of Copenhagen Centre for Translational Research, Bispebjerg and Frederiksberg Hospital.

## Current Positions

Head of Copenhagen Centre for Translational Research (60% position at Department of Biochemistry Bispebjerg and Frederiksberg Hospital) & Chief Physician and Clinical Associate Professor (40% position at the Department of Clinical Pharmacology, Bispebjerg Hospital). Responsibilities include Research management of translational research and phase one clinical trials (Zelo Phase one trial unit), medication reviews at outpatient clinics, function as a clinical toxicologist on-call at the national poison information center (Gifflinjen).

## Honorary Positions

Dr. Mikkel Christensen is involved in several national and regional councils that evaluate pharmacotherapy and thereby impact rational use of medicines in Denmark. Ongoing from 2014: Chairman of the endocrinology group by the Capital Region's Medicines Committee (Den Regionale Lægemedikalkomite). Ongoing from 2016: Part of working group National Recommendation List (Den Nationale Rekommandationsliste) from the Danish Health Authority (Sundhedsstyrelsen) appointed by Danish Society of Clinical Pharmacology. From 2019: Member of the national Danish Medicines Council (Medicinerådet) "workgroup on type 2 diabetes" appointed by Danish Society of Clinical Pharmacology.

## Recent Selected Awards and Grants

Awards: Awarded talent price from the Bagger-Sørensen foundation (2015), Young investigator of the year, Scandinavian Society for the Study of Diabetes (2012); Grants: Research grants from the Capital region of Denmark, University of Copenhagen, Danish Diabetes Association, Beckett-foundation and Tryg Foundation - total funding amounting to &gt; € 2,000,000.

## Publications, Citations and H-Indices

Research primarily within the areas: Clinical pharmacology, polypharmacy, medication review, diabetology, and medicines safety/toxicology (see full publication list on Google Scholar: Mikkel Christensen). Author of several textbook chapters and >120 scientific publications (68 original articles, 34 scientific reviews/proceedings, 25 commentaries/editorials/letters/case reports). >100 Danish and international scientific presentations. Impact Citations: ~ Citations: ~ 4279 (Google Scholar), ~2.671 (Web of Science). H-indices: 30 (Google Scholar), 29 (Web of Science); Scopus Author ID: 32067543900; ResearcherID: H-5861-2013; <https://orcid.org/0000-0002-8774-1797>

## Supervising, Evaluation and Teaching Experience

Supervisor for 17 PhD students - 4 as primary supervisor (1 completed) and 13 as co-supervisor (4 completed) in clinical pharmacology, metabolism and toxicology. Extensive pre- and postgraduate teaching experience in physiology, pharmacology, toxicology and diabetology. Since 2013 clinical associate professor responsible for lectures, teaching and examination at University of Copenhagen course in clinical pharmacology (30 hours annually).

## Summary of Own Research

Ongoing since 2008, I have been an active researcher in topics relating to clinical metabolism and pharmacology. My metabolic research has contributed significantly to understanding the action of endogenous hormones in diabetes and postprandial metabolism, particularly glucose and bone homeostasis and appetite regulation in humans. I am currently exploring interventions to avoid hypoglycemia in patients with diabetes. My research has among other things led to a patent (WO2016034186A1) that is currently investigated as treatment against obesity and other metabolic disorders. Since 2013 I have described various aspects and challenges with polypharmacy and how to deal with this by revising medication lists (Medication reviews). In 2017, I obtained funding to and initiated the Polypharmacy Outpatient Clinic at Bispebjerg and Frederiksberg Hospital. This clinic is now responsible for reviewing medications in complex patients with multiple diseases and pharmacological treatments and have shown great results with regards to improvements in pharmacotherapy and health-related quality of life (results awaiting publication).

## Research outputs

### **Intravenous Oxytocin Has no Effect on Ad Libitum Food Intake or Postprandial Plasma Glucose Concentrations in Individuals With Obesity: A Randomised, Placebo-Controlled, Double-Blind, Crossover Study**

Gether, I. M., Kliim-Hansen, V., Olafsson, P. T., Pedersen, M. G., Nielsen, C. K., Ellegaard, A.-M., Christensen, M. B., Rehfeld, J. F., Helge, J. W., Holst, J. J., Hartmann, B., Knop, F. K., Gasbjerg, L. S. & Lund, A. B., 10 Mar 2026, (E-pub ahead of print) In: *Diabetes, Obesity and Metabolism*.

### **Glucose-dependent insulinotropic polypeptide reduces postprandial glucose excursions but does not protect from hypoglycaemia in persons with type 1 diabetes-A randomised placebo-controlled study**

Hoe, B., Heimbürger, S. M. N., Gasbjerg, L. S., Lanng, A. R., Lynggaard, M. B., Lund, A. B., Dela, F., Faber, J., Skov-Jepesen, K., Engberg, S., Hartmann, B., Holst, J. J., Vilsbøll, T., Christensen, M. B., Dejgaard, T. F. & Knop, F. K., Mar 2026, In: *Diabetes, Obesity and Metabolism*. 28, 3, p. 1886-1898 13 p.

### **The separate and combined effects of GIP, GLP-1 and GLP-2 on markers of bone turnover in type 2 diabetes**

Hansen, J. V., Mathiesen, D. S., Christensen, M. B., Jørgensen, N. R., Helsted, M. M., Bagger, J. I., Holst, J. J., Vilsbøll, T., Knop, F. K. & Lund, A. B., 20 Feb 2026, In: *The Journal of clinical endocrinology and metabolism*. 111, 3, p. e853-e859

### **Glucose-Dependent Effects of Exogenous Glucagon-Like Peptide-2 on Circulating Glucagon Levels in Healthy Men**

Sørum, N. E., Magnussen, T., Hansen, N. L., Nielsen, C. K., Holst, J. J., Hartmann, B., Henriksen, K., Størling, J., Faber, J., Christensen, M. B., Lund, A. B. & Knop, F. K., 1 Feb 2026, In: *Journal of the Endocrine Society*. 10, 2, p. bvaf215 bvaf215.

### **Identifying 20 homogeneous clusters of acute patients discharged with nonspecific diagnoses through k-prototypes mixed data clustering**

Gregersen, R., Villumsen, M., Nyström, A., Nygaard, H., Rasmussen, J., Christensen, M. B., Forberg, J. L. & Petersen, J., 10 Jan 2026, In: *BMC Emergency Medicine*. 26, 1, 44.

### **Intravenous Arginine Stimulates Glucagon Secretion More Than Equimolar Alanine, Leucine, Glutamine, and Proline in Humans**

Suppli, M. P., Høgedal, A., Bagger, J. I., Grøndahl, M. F. G., Forman, J. L., Trammell, S. A. J., Vranešević, A., Grevengoed, T. J., Vilstrup, H., Christensen, M. B., Wewer Albrechtsen, N. J., Lund, A. B., Holst, J. J. & Knop, F. K., 1 Oct 2025, In: *Journal of the Endocrine Society*. 9, 10, p. bvaf139 bvaf139.

**Effects of a six-week continuous s.c. infusion of GIP alone or in combination with once-weekly s.c. semaglutide on bone turnover markers**

Fonnesbech-Wulf, C., Helsted, M. M., Schaltz, N. L., Lund, I. W., Forman, J. L., Nielsen, C., Englund, A., Hartmann, B., Vilsbøll, T., Holst, J. J., Lund, A. B., Christensen, M. B., Knop, F. K. & Gasbjerg, L. S., Oct 2025, In: *Diabetologia*. 68, suppl 1, p. S674 LBA 55.

**Six-week continuous s.c. infusion of GIP alone or added to semaglutide treatment had no effect on mean glucose levels or body weight in individuals with type 2 diabetes**

Helsted, M. M., Fonnesbech-Wulf, C., Schaltz, N. L., Lund, I. W., Forman, J., Nielsen, C. K., Englund, A., Hartmann, B., Vilsbøll, T., Holst, J. J., Lund, A. B., Christensen, M. B., Knop, F. K. & Gasbjerg, L. S., Sept 2025, In: *Diabetologia*. 68, Suppl 1, p. S44 77.

**The glucagonotropic effect of glucose-dependent insulinotropic polypeptide is negated during insulin-induced hypoglycaemia in persons with type 1 diabetes**

Sørum, N. E., Nielsen, J. V. W., Holst, J. J., Hartmann, B., Gasbjerg, L. S., Størling, J., Dejgaard, T. F., Christensen, M. B., Campbell, J. E., Knop, F. K. & Lund, A. B., Sept 2025, In: *Diabetologia*. 68, Supp 1, p. S51 91.

**25 forskere og læger: Der er et påtrængende behov for en national strategi for forskning i ældres sundhed**

Suetta, C. A., Helge, J. W., Schultz, M., Waldorf, F. B., Holm, E. A., Christensen, M. B., Kjaer, M., Linneberg, A., Sørensen, T. L., Overgaard, S., Møller, T., Holm, A., Kristiansen, M., Tetens, I., Hansen, J. P., Eiken, P., Kristensen, M. T., Nielsen, D. S., Kayser, L. & Zebis, M. K. & 5 others, Kruuse, C. R., Jespersen, A. P., Scheibye-Knudsen, M., Beck, A. M. & Jørgensen, N. R., 18 Aug 2025, In: *Altinget*.

**GIP Alone or with GLP-1RA Had No Detectable Effect on Glucose Levels in Individuals with Type 2 Diabetes**

Helsted, M. M., Fonnesbech-Wulf, C. C., Schaltz, N. L., Lund, I. W., Forman, J., Nielsen, C. K., Englund, A., Hartmann, B., Vilsbøll, T., Holst, J. J., Lund, A. B., Christensen, M. B., Knop, F. K. & Gasbjerg, L. S., Jun 2025, In: *Diabetes*. 74, Suppl 1, 2 p.

**Drug exposure and measurable residual disease in chronic lymphocytic leukemia: a systematic review**

Korsholm, C., Bülow, C., Christensen, M., Dalhoff, K., Feinberg, J. B., Lund, T. M., Niemann, C. U., Petersen, T. S. & Andersen, M. A., Feb 2025, In: *Leukemia and Lymphoma*. 66, 2, p. 229-239 11 p.

**The Effect of Exercise on Pharmacodynamics and Pharmacokinetics of a Single Dose of Unfractionated Heparin-A Randomized, Controlled, Crossover Study**

Stuhr, L. K., Feinberg, J. B., Christoffersen, T., Dimopoulos, K., Christensen, M. B., Sonne, D. P., Riis, T., Plomgaard, P. S., Goetze, J. P., Larsen, E. L. & Karstoft, K., Jan 2025, In: *Clinical and Translational Science*. 18, 1, e70113.

**Increasing Medication Use and Polypharmacy in Type 2 Diabetes: The Danish Experience From 2000 to 2020**

Johansson, K. S., Jimenez Solem, E., Petersen, T. S. & Christensen, M. B., 1 Dec 2024, In: *Diabetes spectrum : a publication of the American Diabetes Association*. 47, 12, p. 2120-2127 8 p.

**Secretin infusion decreases food intake in healthy men - a randomized, placebo-controlled, double-blind, crossover study**

Heimbürger, S. M. N., Bentzen, M. J., Kizilkaya, H. S., Hartmann, B., Holst, J. J., Rosenkilde, M. M., Dela, F., Hansen, S. H., Rehfeld, J. F., Christensen, M. B. & Knop, F. K., Dec 2024, In: *European Journal of Endocrinology*. 191, 6, p. 545-557 13 p.

**Patients' knowledge of the indications for their medications - a scoping review**

Bülow, C., Clausen, S. S., Thøgersen, P. L., Dalin, D. A., Hansen, J. M., Johansson, K. S., Lundh, A. & Christensen, M. B., 8 Oct 2024, In: *BMC Health Services Research*. 24, 1, p. 1195 1195.

**Glucagon Clearance is Decreased in Chronic Kidney Disease, but Preserved in Liver Cirrhosis**

Grøndahl, M. F. G., Lange, A. H., Suppli, M. P., Bagger, J. I., Thing, M., Gluud, L. L., Kofod, D. H., Hornum, M., Van Hall, G., Trammell, S. A. J., Grevengoed, T. J., Hartmann, B., Holst, J. J., Vilsbøll, T., Christensen, M. B., Lund, A. B. & Knop, F. K., 1 Oct 2024, In: *Diabetes*. 73, 10, p. 1641-1647 7 p.

**Rational Pharmacotherapy in Type 2 Diabetes: Danish Data From 2002 to 2020 on Mortality, Diabetes-Related Outcomes, Adverse Events, and Medication Expenses**

Johansson, K. S., Jimenez-Solem, E., Petersen, T. S. & Christensen, M. B., Sept 2024, In: *Diabetes Care*. 47, 9, p. 1656-1663 8 p.

**Safety of native glucose-dependent insulinotropic polypeptide in humans**

Helsted, M. M., Schaltz, N. L., Gasbjerg, L. S., Christensen, M. B., Vilsbøll, T. & Knop, F. K., Jul 2024, In: *Peptides*. 177, p. 171214 171214.

**Farmakologisk behandling af type 2-diabetes i almen praksis med fokus på fremtidig tilskudsstatus for glukosesænkende lægemidler**

Halmsted Olsen, J. H., Christensen, M. B., Brønden, A., Karstoft, K., Kristensen, J. K. & Glintborg, D., Jun 2024, In: *Rationel farmakoterapi* [online]. 2024, 3

**Acute patients discharged without an established diagnosis: risk of mortality and readmission of nonspecific diagnoses compared to disease-specific diagnoses**

Gregersen, R., Villumsen, M., Mottlau, K. H., Maule, C. F., Nygaard, H., Rasmussen, J. H., Christensen, M. B. & Petersen, J., 19 Apr 2024, In: *Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine*. 32, 1, p. 32 32.

**Treatment of nausea in hospitalized patients with acute illness**

Nersesjan, M., Nersesjan, S. C., Pedersen, L. & Christensen, M. B., 15 Apr 2024, In: *Ugeskrift for Laeger*. 186, 16

**Signs of Glucagon Resistance After a 2-Week Hypercaloric Diet Intervention**

Suppli, M. P., Høgedal, A., Bagger, J. I., Chabanova, E., van Hall, G., Forman, J. L., Christensen, M. B., Albrechtsen, N. J. W., Holst, J. J. & Knop, F. K., 1 Apr 2024, In: *The Journal of clinical endocrinology and metabolism*. 109, 4, p. 955-967 13 p.

**The effect of exogenous glucagon on circulating amino acids in individuals with and without type 2 diabetes and obesity**

Grøndahl, M. F. G., Bagger, J. I., Suppli, M. P., van Hall, G., Albrechtsen, N. J. W., Holst, J. J., Vilsbøll, T., Christensen, M. B., Lund, A. B. & Knop, F. K., 1 Mar 2024, In: *Endocrine Connections*. 13, 3, e230516.

**The development of type 2 diabetes management in people with severe mental illness in the Capital Region of Denmark from 2001 to 2015**

Bakkedal, C., Persson, F., Christensen, M. B., Kriegbaum, M., Mohr, G. H., Andersen, J. S., Lind, B. S., Lykkegaard, C., Siersma, V. & Rozing, M. P., Mar 2024, In: *Acta Psychiatrica Scandinavica*. 149, 3, p. 219-233 15 p.

**Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial**

Holm-Weber, T., Skov, F., Mohanakumar, S., Thorup, L., Riis, T., Christensen, M. B., Sonne, D. P., Jensen, P. B., Bødtkjer, D. B. & Hjortdal, V. E., 2 Jan 2024, In: *European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery*. 65, 1, p. 1-9 9 p., ezad380.

**Non-Insulin Parenteral Therapies**

Vilsbøll, T., Christensen, M. B., Andersen, A. & Knop, F. K., Jan 2024, *Textbook of Diabetes, 6th Edition*. Holt, R. I. G. & Flyvbjerg, A. (eds.). Wiley-Blackwell, p. 520-533 14 p.

**The impact of type 2 diabetes and glycaemic control on mortality and clinical outcomes in hospitalized patients with COVID-19 in the capital region of Denmark**

Kliim-Hansen, V., Johansson, K. S., Gasbjerg, L. S., Jimenez-Solem, E., Petersen, T. S., Nyeland, M. E., Winther-Jensen, M., Ankarfeldt, M. Z., Pedersen, M. G., Ellegaard, A.-M., Knop, F. K. & Christensen, M. B., Jan 2024, In: *Diabetes, Obesity and Metabolism*. 26, 1, p. 160-168 9 p.

**The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects**

Jensen, T. L., Brønden, A., Christensen, M. B., Karstoft, K. & Sonne, D. P., 2024, In: *Patient Preference and Adherence*. 18, p. 373-382 10 p.

**The separate and combined effects of glucose-dependent insulinotropic polypeptide and alanine on plasma glucose during fasting in healthy individuals**

Thomas, A. M., Warnøe, J. V., Mathiesen, D. S., Preskou, E. M., Dejgaard, T. F., Lund, A., Størling, J., Christensen, M. B., Gasbjerg, L. S. & Knop, F. K., 2024, In: *Diabetologia*. 67, Suppl 1, 539.

**Age disparities in glucose-lowering treatment for Danish people with type 2 diabetes: a cross-sectional study between 2019 and 2020**

Johansson, K. S., Bülow, C., Jimenez-Solem, E., Petersen, T. S. & Christensen, M. B., Dec 2023, In: *The Lancet Healthy Longevity*. 4, 12, p. e685-e692

**Impact of multimorbidity and polypharmacy on mortality after cancer: a nationwide registry-based cohort study in Denmark 2005-2017**

Thomsen, M. K., Løppenthin, K. B., Bidstrup, P. E., Andersen, E. W., Dalton, S., Petersen, L. N., Pappot, H., Mortensen, C. E., Christensen, M. B., Frølich, A., Lassen, U. & Johansen, C., Dec 2023, In: *Acta Oncologica*. 62, 12, p. 1653-1660 8 p.

**Medication changes implemented during medication reviews and factors related to deprescribing: Posthoc analyses of a randomized clinical trial in geriatric outpatients with polypharmacy**

Kornholt, J., Feizi, S. T., Hansen, A. S., Laursen, J. T., Johansson, K. S., Reuther, L. Ø., Petersen, T. S., Pressel, E. & Christensen, M. B., Nov 2023, In: *British Journal of Clinical Pharmacology*. 89, 11, p. 3291-3301 11 p.

**Methodological Considerations for Describing Medication Changes in Relation to Clinical Events and Death: An Applied Example in Patients with Type 2 Diabetes and Cancer**

Johansson, K. S., Petersen, T. S., Christensen, M. B. & Pottegård, A., Nov 2023, In: *Drugs & Aging*. 40, 11, p. 1009-1015 7 p.

**Medicinnemngange? Ja tak, men hvor og hvordan?**

Christensen, M. B., Bülow, C. & Lundh, A., 16 Oct 2023, In: *Ugeskrift for Læger*. 185:V205151.

**The impact of type 2 diabetes and glycaemic control on mortality and clinical outcomes in hospitalised patients with COVID-19 in the capital region of Denmark**

Kliim-Hansen, V., Johansson, K. S., Gasbjerg, L. S., Jimenez-Solem, E., Petersen, T. S., Nyeland, M. E., Ellegaard, A.-M., Pedersen, M. G., Knop, F. K. & Christensen, M. B., 1 Sept 2023, In: *Diabetologia*. 66, SUPPL 1, 1, p. S488

**Effects of DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors and sulphonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: A network meta-analysis-driven approach**

Brønden, A., Christensen, M. B., Glinborg, D., Snorgaard, O., Kofoed-Enevoldsen, A., Madsen, G. K., Tofft, K., Kristensen, J. K., Højlund, K., Hansen, T. K., Søndergaard, E. & Hansen, K. B., Aug 2023, In: *Diabetic medicine : a journal of the British Diabetic Association*. 40, 8, p. e15157 e15157.

**Physician-led medication reviews in a type 2 diabetes outpatient clinic: a randomised trial**

Johansson, S., Kornholt, J., Bulow, C., Petersen, T. S., Perrild, H., Rungby, J. & Christensen, M. B., 1 Jul 2023, In: *British Journal of Pharmacology*. 180, 1, p. 317 1 p.

**Diabetes treatment for persons with severe mental illness: A registry-based cohort study to explore medication treatment differences for persons with type 2 diabetes with and without severe mental illness**

Bakkedal, C., Persson, F., Kriegbaum, M., Andersen, J. S., Grant, M. K., Mohr, G. H., Lind, B. S., Andersen, C. L., Christensen, M. B., Siersma, V. & Roizing, M. P., 13 Jun 2023, In: *PLoS One*. 18, 6, e0287017.

**The association between paracetamol dose/plasma concentration and the severity of methemoglobinemia: a case-control study**

Petersen, T. S., Daoud, A., Bøgevig, S., Høgberg, L. C. G. & Christensen, M. B., 23 May 2023, p. 117. 129 p.

**Insulin kinetics in high dose insulin therapy—a human randomized controlled trial**

Bøgevig, S., Petersen, T. S., Riis, T., Bronden, A., Praeger-Jahnsen, L., Friis-Hansen, L., Høgberg, L. C. G. & Christensen, M. B., 16 May 2023, p. 85. 129 p.

**Paracetamol medication errors are associated with a high risk of hepatotoxicity in children aged 0–6 years: a retrospective cohort study**

Daoud, A., Gade, C., Bøgevig, S., Christensen, M. B., Dalhoff, K. P. & Petersen, T. S., 16 May 2023, p. 47. 129 p.

**Continuous renal replacement therapy (CRRT) removal capacity of selected pharmaceuticals in high concentrations, a whole blood (swine) in vitro model**

Christensen, M. B., Høgberg, L. C. G., Hermann, D., Riis, T., Hannibal, J. & Bøgevig, S., May 2023.

**Safety of glucagon-like peptide-1 receptor agonists for weight management in adults, adolescents, and children with obesity: A scoping review**

Baden, C. S., Andersen, J. T., Christensen, M. B. & Gade, C., 1 Apr 2023, In: Adverse Drug Reaction Bulletin. 339, 1, p. 1315-1318 4 p.

**Physician-led medication reviews in polypharmacy patients treated with at least 12 medications in a type 2 diabetes outpatient clinic: A randomised trial**

Johansson, K. S., Kornholt, J., Bülow, C., Petersen, T. S., Perrild, H., Rungby, J. & Christensen, M. B., Apr 2023, In: Diabetic medicine : a journal of the British Diabetic Association. 40, 4, p. e15052 e15052.

**Protocol for assessing the effects of exogenous hormone administration on human postprandial glucose metabolism, appetite sensations, and food intake**

Hagemann, C. A., Gasbjerg, L. S., Christensen, M. B. & Knop, F. K., 17 Mar 2023, In: STAR Protocols. 4, 1, 102070.

**Tirzepatide. Dual GLP-1/GIP receptor agonist, Treatment of type 2 diabetes and obesity**

Jensen, T. L., Bronden, A., Karstoft, K., Christensen, M. B. & Sonne, D. P., Mar 2023, In: Drugs of the Future. 48, 3, p. 179-196 18 p.

**Separate and combined effects of long-term GIP and GLP-1 receptor activation in patients with type 2 diabetes: a structured summary of a study protocol for a double-blind, randomised, placebo-controlled clinical trial**

Helsted, M. M., Gasbjerg, L. S., Vilsbøll, T., Nielsen, C. K., Forman, J. L., Christensen, M. B. & Knop, F. K., 27 Feb 2023, In: BMJ Paediatrics Open. 13, 2, e065736.

**Medication review in hospitalised patients to reduce morbidity and mortality**

Bülow, C., Clausen, S. S., Lundh, A. & Christensen, M., 23 Jan 2023, In: Cochrane Database of Systematic Reviews. 2023, 1, p. CD008986 CD008986.

**Scoping Review of Randomized Trials With Discontinuation of Medicines in Older Adults**

Kornholt, J., Bülow, C., Sørensen, A. M. S., Pressel, E., Petersen, T. S. & Christensen, M. B., Dec 2022, In: Journal of the American Medical Directors Association. 23, 12, p. 1926.e11-1926.e35 25 p.

**Protocol for a 30-day randomised, parallel-group, non-inferiority, controlled trial investigating the effects of discontinuing renin-angiotensin system inhibitors in patients with and without COVID-19: the RASCOVID-19 trial**

Kliim-Hansen, V., Gasbjerg, L. S., Ellegaard, A.-M., Lorentsson, H. J. N., Lynggaard, M. B., Hagemann, C. A., Legart, C., Mathiesen, D. S., Sivapalan, P., Jensen, J.-U. S., Vilsbøll, T., Christensen, M. B. & Knop, F. K., 30 Nov 2022, In: BMJ Paediatrics Open. 12, 11, p. e062895 8 p., e062895.

**GIP Affects Hepatic Fat and Brown Adipose Tissue Thermogenesis but Not White Adipose Tissue Transcriptome in Type 1 Diabetes**

Heimbürger, S. M. N., Hoe, B., Nielsen, C. N., Bergman, N. C., Skov-Jepesen, K., Hartmann, B., Holst, J. J., Dela, F., Overgaard, J., Størling, J., Vilsbøll, T., Dejgaard, T. F., Havelund, J. F., Gorshkov, V., Kjeldsen, F., Færgeman, N. J. K., Madsen, M. R., Christensen, M. B. & Knop, F. K., 25 Nov 2022, In: The Journal of clinical endocrinology and metabolism. 107, 12, p. 3261-3274 14 p.

## **Evidensbaseret medicin**

Christensen, M. B., 12 Oct 2022, *Evidensbaseret medicin*. Hammen, L. N. (ed.). 1 ed. Vol. 1. 560 p.

### **Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in $\beta$ -Cell Function in Patients With Type 2 Diabetes**

Stensen, S., Gasbjerg, L. S., Rosenkilde, M. M., Vilsbøll, T., Holst, J. J., Hartmann, B., Christensen, M. B. & Knop, F. K., 1 Oct 2022, In: *Diabetes*. 71, 10, p. 2209-2221 13 p.

### **Acute concomitant glucose-dependent insulinotropic polypeptide receptor antagonism during glucagon-like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity**

Stensen, S., Krogh, L. L., Sparre-Ulrich, A. H., Dela, F., Hartmann, B., Vilsbøll, T., Holst, J. J., Rosenkilde, M. M., Christensen, M. B., Gasbjerg, L. S. & Knop, F. K., Sept 2022, In: *Diabetes, Obesity and Metabolism*. 24, 9, p. 1882-1887 6 p.

### **Endogenous glucose-dependent insulinotropic polypeptide (GIP) facilitates postprandial intestinal lipid uptake**

Gasbjerg, L. S., Helsted, M. M., Stensen, S., Krogh, L. S. L., Sparre-Ulrich, A. H., Hartmann, B., Vilsbøll, T., Christensen, M. B., Holst, J. J., Christoffersen, C., Knop, F. K. & Rosenkilde, M. M., Sept 2022, In: *Diabetologia*. 65, SUPPL 1, p. S260-S260

### **Effects of a comprehensive medication review intervention on health-related quality of life and other clinical outcomes in geriatric outpatients with polypharmacy: A pragmatic randomized clinical trial**

Kornholt, J., Feizi, S. T., Hansen, A. S., Laursen, J. T., Reuther, L. Ø., Petersen, T. S., Pressel, E. & Christensen, M. B., Jul 2022, In: *British Journal of Clinical Pharmacology*. 88, 7, p. 3360-3369 10 p.

### **Short-term mortality following tramadol poisonings in Denmark**

Sørensen, A. M. S., Petersen, J., Christensen, M. B., Schelde, A. B., Andersen, J. T., Jimenez Solem, E. & Petersen, T. S., Jul 2022, In: *Basic and Clinical Pharmacology and Toxicology*. 131, 1, p. 83-92 10 p.

### **The Impact of Diabetes on Mortality and Clinical Outcomes in Hospitalized Patients with COVID-in the Capital Region of Denmark**

KLIIM-HANSEN, V., Nyeland, M. E., Gasbjerg, L. S., Jimenez Solem, E., Petersen, T. S., Ellegaard, A. M., Knop, F. K. & Christensen, M. B., Jun 2022, In: *Diabetes*. 71, 1, 1217-P.

### **Drug use in patients with short bowel syndrome and intestinal failure**

Vorre, M. M., Johansson, K. S., Fuglsang, K. A., Horwitz, H., Solem, E. J., Jeppesen, P. B. & Christensen, M. B., 28 Apr 2022, In: *Danish Medical Journal*. 69, 5

### **LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men**

Hagemann, C. A., Jensen, M. S., Holm, S., Gasbjerg, L. S., Byberg, S., Skov-Jeppesen, K., Hartmann, B., Holst, J. J., Dela, F., Vilsbøll, T., Christensen, M. B., Holst, B. & Knop, F. K., 19 Apr 2022, In: *Cell reports. Medicine*. 3, 4, p. 100582 100582.

### **Has the time come to stop routine N-acetylcysteine treatment in young children in Denmark? A review of 300 suspected paracetamol overdoses in children aged 0-6 years**

Gade, C., Bøgevig, S., Daoud, A., Mathiesen, P. R., Christensen, M. B., Peder Dalhoff, K. & Petersen, T. S., Mar 2022, In: *Acta paediatrica*. 111, 3, p. 667-674 8 p.

### **VEuPathDB: the eukaryotic pathogen, vector and host bioinformatics resource center**

Amos, B., Aurrecochea, C., Barba, M., Barreto, A., Basenko, E. Y., Bazant, W., Belnap, R., Blevins, A. S., Böhme, U., Brestelli, J., Brunk, B. P., Caddick, M., Callan, D., Campbell, L., Christensen, M. B., Christophides, G. K., Crouch, K., Davis, K., DeBarry, J. & Doherty, R. & 46 others, Duan, Y., Dunn, M., Falke, D., Fisher, S., Flicek, P., Fox, B., Gajria, B., Giraldo-Calderón, G. I., Harb, O. S., Harper, E., Hertz-Fowler, C., Hickman, M. J., Howington, C., Hu, S., Humphrey, J., Iodice, J., Jones, A., Judkins, J., Kelly, S. A., Kissinger, J. C., Kwon, D. K., Lamoureux, K., Lawson, D., Li, W., Lies, K., Lodha, D., Long, J., MacCallum, R. M., Maslen, G., McDowell, M. A., Nabrzyski, J., Roos, D. S., Rund, S. S. C., Schulman, S. W., Shanmugasundram, A., Sitnik, V., Spruill, D., Starns, D., Stoeckert, C. J., Tomko, S. S., Wang, H.,

Warrenfeltz, S., Wieck, R., Wilkinson, P. A., Xu, L. & Zheng, J., 7 Jan 2022, In: Nucleic Acids Research. 50, D1, p. D898-D911

#### **Glucagon Clearance is Preserved in Type 2 Diabetes**

Grøndahl, M. F. G., Lund, A., Bagger, J. I., Petersen, T. S., Wewer Albrechtsen, N. J., Holst, J. J., Vilsbøll, T., Christensen, M. B. & Knop, F. K., Jan 2022, In: Diabetes. 71, 1, p. 73-82 10 p.

#### **Glucose-dependent insulinotropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: a randomized, double-blind, placebo-controlled, crossover clinical trial**

Heimbürger, S. M., Nielsen, C. N., Calanna, S., Holst, J. J., Vilsbøll, T., Knop, F. K. & Christensen, M. B., Jan 2022, In: Diabetes, Obesity and Metabolism. 24, 1, p. 142-147 6 p.

#### **Acute changes in plasma glucose increases left ventricular systolic function in insulin-treated patients with type 2 diabetes and controls**

Andersen, A., Jørgensen, P. G., Bagger, J. I., Baldassarre, M. P. A., Christensen, M. B., Pedersen-Bjergaard, U., Lindhardt, T. B., Gislason, G., Knop, F. K. & Vilsbøll, T., 2022, In: Diabetes, Obesity and Metabolism. 24, 6, p. 1123-1131 9 p.

#### **Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes**

Kim, A., Knudsen, J. G., Madara, J. C., Benrick, A., Hill, T. G., Abdul Kadir, L., Kellard, J. A., Mellander, L., Miranda, C., Lin, H., James, T., Suba, K., Spigelman, A. F., Wu, Y., MacDonald, P. E., Wernstedt Asterholm, I., Magnussen, T., Christensen, M., Vilsbøll, T. & Salem, V. & 4 others, Knop, F. K., Rorsman, P., Lowell, B. B. & Briant, L. J., 17 Nov 2021, In: eLife. 10, e72919.

#### **Exendin(9-39)NH<sub>2</sub> - recommendations for clinical use based on a systematic literature review**

Gasbjerg, L. S., Bari, E. J., Christensen, M. B. & Knop, F. K., Nov 2021, In: Diabetes, Obesity and Metabolism. 23, 11, p. 2419-2436 18 p.

#### **The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial**

Heimbürger, S. M. N., Hoe, B., Nielsen, C. N., Bergmann, N. C., Hartmann, B., Holst, J. J., Vilsbøll, T., Dejgaard, T. F., Christensen, M. B. & Knop, F. K., Nov 2021, In: Diabetologia. 64, 11, p. 2425-2431 7 p.

#### **MECHANISMS IN ENDOCRINOLOGY: The physiology of neuronostatin**

Andersen, M. R., Suppli, M. P., Bagger, J. I., Christensen, M. B., Yosten, G. L. C., Knop, F. K. & Lund, A., 1 Sept 2021, In: European Journal of Endocrinology. 185, 4, p. R93-R101

#### **Causes of discrepancies between medications listed in the national electronic prescribing system and patients' actual use of medications**

Bülow, C., Noergaard, J. D. S. V., Faerch, K. U., Pontoppidan, C., Unkerskov, J., Johansson, K. S., Kornholt, J. & Christensen, M. B., Sept 2021, In: Basic and Clinical Pharmacology and Toxicology. 129, 3, p. 221-231 11 p.

#### **Exogenous LEAP2 improves postprandial glucose tolerance and reduces ad libitum food intake in men**

Hagemann, C. A., Jensen, M. S., Holm, S., Gasbjerg, L. S., Christensen, M. B., Heimbürger, S. M. N., Dela, F., Vilsboll, T., Holst, B. & Knop, F. K., Sept 2021, p. 23-23.

#### **Exogenous secretin decreases ad libitum food intake and exhibits a biphasic effect on supraclavicular brown adipose tissue activity in healthy men**

Bentzen, M. J., Heimbürger, S. M. N., Hartmann, B., Holst, J. J., Christensen, M. B. & Knop, F. K., Sept 2021, p. 211. 1 p.

#### **Glucose-dependent insulinotropic polypeptide (GIP) contributes to sitagliptin-mediated improvement of beta cell function in patients with type 2 diabetes**

Stensen, S., Gasbjerg, L. S., Rosenkilde, M. M., Hartmann, B., Vilsboll, T., Holst, J. J., Christensen, M. B. & Knop, F. K., Sept 2021, p. 95-95.

**Six-day sc GIP infusion increases plasma NEFA without altering the adipose tissue transcriptome, GIPR levels or plasma markers of inflammation in patients with type 1 diabetes**

Heimbürger, S. M. N., Hoe, B., Nielsen, C. N., Hartmann, B., Holst, J. J., Dela, F., Overgaard, J., Størling, J., Vilsbøll, T., Dejgaard, T. F., Pyke, C., Christensen, M. B. & Knop, F. K., Sept 2021, p. 258-258. 1 p.

**Pancreatic polypeptide: A potential biomarker of glucose-dependent insulinotropic polypeptide receptor activation in vivo**

Veedfald, S., Bergmann, N. C., Vilsbøll, T., Christensen, M. B., Holst, J. J. & Knop, F. K., Aug 2021, In: Diabetic Medicine. 38, 8, p. e14592 e14592.

**Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls**

Andersen, A., Bagger, J. I., Baldassarre, M. P., Christensen, M. B., Abelin, K. U., Faber, J., Pedersen-Bjerggaard, U., Holst, J. J., Lindhardt, T. B., Gislason, G. H., Knop, F. K. & Vilsbøll, T., 21 Jul 2021, In: European Journal of Endocrinology. 185, 2, p. 343-353 11 p.

**Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity**

Jepsen, M. M. & Christensen, M. B., 3 Jul 2021, In: Expert Opinion on Emerging Drugs. 26, 3, p. 231-243 13 p.

**Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998-2018**

Christensen, M. B., Jimenez-Solem, E., Ernst, M. T., Schmidt, M., Pottgård, A. & Grove, E. L., 30 Jun 2021, In: Scientific Reports. 11, 1, p. 13603 1 p.

**Effects of Exogenous Secretin on Postprandial Plasma Glucose and Lipids and Gallbladder Motility and Hemodynamics in Man**

Bentzen, M. J., Heimbürger, S. M. N., Hartmann, B., Holst, J. J., Christensen, M. B. & Knop, F. K., Jun 2021.

**Exogenous Secretin Decreases Energy Intake and Exerts a Bimodular Effect on Postprandial Brown Adipose Tissue Activation in Man**

Heimbürger, S. M. N., Bentzen, M. J., Hartmann, B., Holst, J. J., Christensen, M. B. & Knop, F. K., Jun 2021.

**Glucose -Dependent Insulinotropic Polypeptide (GIP) Contributes Substantially to the Improved Beta -Cell Function during Sitagliptin Treatment in Persons with Type 2 Diabetes**

Stensen, S., Gasbjerg, L. S., Rosenkilde, M. M., Hartmann, B., Vilsbøll, T., Holst, J. J., Christensen, M. B. & Knop, F. K., Jun 2021.

**Six-Day Subcutaneous GIP Infusion Increases Circulating Free Fatty Acids without Altering the Adipose Tissue Transcriptome, Adipocyte GIP Receptor Levels, or Circulating Inflammation Markers in Patients with Type 1 Diabetes**

Heimbürger, S. M. N., Hoe, B., Nielsen, C. N., Hartmann, B., Holst, J. J., Dela, F., Overgaard, A. J., Størling, J., Vilsbøll, T., Dejgaard, T. F., Pyke, C., Christensen, M. B. & Knop, F. K., Jun 2021.

**The Glucagonotropic Effect of GLP-2 during Hypoglycemia, Euglycemia, and Hyperglycemia in Healthy Men: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study**

Hansen, N. L., Magnussen, T., Holst, J. J., Hartmann, B., Christensen, M. B., Lund, A. & Knop, F. K., Jun 2021.

**Effects of endogenous GIP in patients with type 2 diabetes**

Stensen, S., Gasbjerg, L. S., Krogh, L. L., Skov-Jepesen, K., Sparre-Ulrich, A. H., Jensen, M. H., Dela, F., Hartmann, B., Vilsbøll, T., Holst, J. J., Rosenkilde, M. M., Christensen, M. B. & Knop, F. K., 21 May 2021, In: European Journal of Endocrinology. 185, 1, p. 33-45 13 p.

**Medication errors in residential facilities based on Danish Poison Information Center inquiries**

Bakkedal, C., Eriksen, K. R., Hansen, N. B., Petersen, T. S., Dalhoff, K. P., Bøgevig, S., Rizing, M. P. & Christensen, M. B., 28 Apr 2021, In: Danish Medical Journal. 68, 5, p. A11200800 A11200800.

**An overview of obesity mechanisms in humans: Endocrine regulation of food intake, eating behaviour and common determinants of body weight**

Theilade, S., Christensen, M. B., Vilsbøll, T. & Knop, F. K., Feb 2021, In: Diabetes, Obesity and Metabolism. 23, S1, p. 17-35 19 p.

#### **Identification and metabolic profiling of a novel human gut-derived LEAP2 fragment**

Hagemann, C. A., Zhang, C., Hansen, H. H., Jorsal, T., Rigbolt, K. T. G., Madsen, M. R., Bergmann, N. C., Heimbürger, S. M. N., Falkenhahn, M., Theis, S., Breitschopf, K., Holm, S., Hedegaard, M. A., Christensen, M. B., Vilsbøll, T., Holst, B., Vrang, N., Jelsing, J. & Knop, F. K., Feb 2021, In: The Journal of clinical endocrinology and metabolism. 106, 2, p. e966-e981

#### **Dose-dependent efficacy of the glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist GIP(3-30)NH<sub>2</sub> on GIP actions in humans**

Gasbjerg, L. S., Bari, E. J., Stensen, S., Hoe, B., Lanng, A. R., Mathiesen, D. S., Christensen, M. B., Hartmann, B., Holst, J. J., Rosenkilde, M. M. & Knop, F. K., Jan 2021, In: Diabetes, Obesity and Metabolism. 23, 1, p. 68-74 7 p.

#### **Anvendt klinisk farmakologi**

Dalhoff, K. P. (Editor), Andersen, S. E. (Editor), Hellebek, A. H., Jürgens, G., Christensen, H. R., Holst, H., Andersen, J. T., Enghusen-Poulsen, H., Christensen, M. B., Horwitz, H., Harboe, K. M., Reuther, L. Ø., Christiansen, M. L. S., Nørgaard, M., Petersen, T. S. & Skov, K., 2021, 1 ed. FADL's Forlag. 260 p.

#### **GIP peptide analogues: US Patent 10,968,266, 2021**

Christensen, M. B. (Inventor), 2021, Patent No. 10968266

#### **Systemisk toksicitet ved lokalanalgetika**

Johansson, K. S., Høgberg, L. C. G., Christensen, M. B., Petersen, T. S., Dalhoff, K. & Bøgevig, S., 14 Dec 2020, In: Ugeskrift for Laeger. 182, 51

#### **Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years**

Gotfredsen, D. R., Vinther, S., Petersen, T. S., Cortes, R., Jensen, T. B., Jimenez-Solem, E. & Christensen, M. B., 1 Dec 2020, In: Scientific Reports. 10, 1, p. 4095 4095.

#### **GIP(3-30)NH<sub>2</sub> - a tool for the study of GIP physiology**

Lynggaard, M. B., Gasbjerg, L. S., Christensen, M. B. & Knop, F. K., Dec 2020, In: Current Opinion in Pharmacology. 55, p. 31-40 10 p.

#### **Multidisciplinær håndtering af svær jernforgiftning som følge af suicidalforsøg**

Petersen, S. M., Boysen, T., Svane, M. S. & Christensen, M. B., 9 Nov 2020, In: Ugeskrift for Laeger. 182, 46

#### **A poison information centre can provide important assessment and guidance regarding medication errors in nursing homes: A prospective cohort study**

Vinther, S., Bøgevig, S., Eriksen, K. R., Hansen, N. B., Petersen, T. S., Dalhoff, K. P. & Christensen, M. B., 4 Nov 2020, In: Basic & clinical pharmacology & toxicology.

#### **High-Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Beta-Adrenoceptor Blockade: A Randomized Clinical Trial**

Petersen, K. M., Bøgevig, S., Riis, T., Andersson, N. W., Dalhoff, K. P., Holst, J. J., Knop, F. K., Faber, J., Petersen, T. S. & Christensen, M. B., 3 Nov 2020, In: Journal of the American Heart Association. 9, 21, p. e016828

#### **The role of endogenous GIP and GLP-1 in postprandial bone homeostasis**

Helsted, M. M., Gasbjerg, L. S., Lanng, A. R., Bergmann, N. C., Stensen, S., Hartmann, B., Christensen, M. B., Holst, J. J., Vilsbøll, T., Rosenkilde, M. M. & Knop, F. K., Nov 2020, In: Bone. 140, p. 115553 115553.

#### **What is on the horizon for type 2 diabetes pharmacotherapy? - An overview of the antidiabetic drug development pipeline**

Johansson, K. S., Sonne, D. P., Knop, F. K. & Christensen, M. B., Nov 2020, In: Expert Opinion on Drug Discovery. 15, 11, p. 1253-1265 13 p.

#### **Medication-related experiences of patients with polypharmacy: a systematic review of qualitative studies**

Eriksen, C. U., Kyriakidis, S., Christensen, L. D., Jacobsen, R., Laursen, J., Christensen, M. B. & Frølich, A., 6 Sept 2020, In: BMJ Paediatrics Open. 10, 9, p. e036158

**Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent**

Jensen, M. E., Galli, A., Thomsen, M., Jensen, K. L., Thomsen, G. K., Klausen, M. K., Vilsbøll, T., Christensen, M. B., Holst, J. J., Owens, A., Robertson, S., Daws, L., Zanella, D., Gether, U., Knudsen, G. M. & Fink-Jensen, A., 1 Sept 2020, In: *Neurochemistry International*. 138, p. 104772-104772.

**Glucose-dependent Insulinotropic Polypeptide (GIP) reduces bone resorption in patients with type 2 diabetes**

Christensen, M. B., Lund, A. B., Jørgensen, N. R., Holst, J. J., Vilsbøll, T. & Knop, F. K., 1 Sept 2020, In: *Journal of the Endocrine Society*. 4, 9, p. bvaa097-bvaa097.

**Cardiovascular effects of high-dose glucagon: a randomised clinical trial**

Petersen, K. M., Bøgevig, S., Riis, T., Andersson, N. A. W., Dalhoff, K. P., Holst, J. J., Knop, F. K., Faber, J., Petersen, T. S. & Christensen, M. B., Sept 2020, p. S231-S231.

**Counterregulatory responses to hypoglycaemia in totally pancreatectomised patients**

Baekdal, M., Lund, A., Baldassarre, M., Rose, K., Egholm, J., Christensen, M. B., Hansen, C. P., Storkholm, J. H., Faber, J., Hartmann, B., Holst, J. J., Vilsbøll, T. & Knop, F. K., Sept 2020, p. S95-S95.

**GIP infusion in patients with type 1 diabetes seems to attenuate post-prandial glucose excursions after prandial insulin over-dose and physical activity**

Hoe, B., Heimbürger, S. M. N., Gasbjerg, L. S., Lanng, A. R., Lynggaard, M. B., Hartmann, B., Holst, J. J., Vilsbøll, T., Lund, A., Engberg, S., Dejgaard, T. F., Christensen, M. B. & Knop, F. K., Sept 2020, p. S117-S117.

**Identification of a gut-derived LEAP2 fragment as a novel insulin secretagogue**

Hagemann, C. A., Zhang, C., Jorsal, T., Rigbolt, K. T., Falkenhahn, M., Theis, S., Christensen, M., Vilsbøll, T., Vrang, N., Jelsing, J. & Knop, F. K., Sept 2020, p. S70-S70.

**Six-day subcutaneous GIP infusion increases glycaemic time in range in patients with type 1 diabetes**

Heimbürger, S. M., Hoe, B., Nielsen, C., Bergmann, N. C., Hartmann, B., Holst, J. J., Størling, J., Vilsbøll, T., Dejgaard, T. F., Christensen, M. B. & Knop, F. K., Sept 2020, p. S73-S73.

**The impact of acute glycaemic fluctuations on left ventricular systolic function in insulin-treated type 2 diabetes**

Andersen, A., Jørgensen, P. G., Bagger, J. I., Baldassarre, M. P. A., Christensen, M., Abelin, K. U., Faber, J., Pedersen-Bjergaard, U., Holst, J. J., Lindhardt, T., Gislason, G., Knop, F. K. & Vilsbøll, T., Sept 2020, p. S429-S429.

**Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication**

Loeppenthin, K., Dalton, S. O., Johansen, C., Andersen, E., Christensen, M. B., Pappot, H., Petersen, L. N., Thisted, L. B., Frølich, A., Mortensen, C. E., Lassen, U., Ørsted, J. & Bidstrup, P. E., Sept 2020, In: *British Journal of Cancer*. 123, 6, p. 1033-1040 8 p.

**Sex and age differences among tramadol users in three Nordic countries**

Schelde, A. B., Sørensen, A. M. S., Hindsø, M., Christensen, M. B., Jimenez-Solem, E. & Eriksson, R., 1 Jul 2020, In: *Danish Medical Journal*. 67, 7, p. 1-12 12 p., A06190336.

**Prevalence of polypharmacy in Denmark**

Kornholt, J. & Christensen, M. B., 1 Jun 2020, In: *Danish Medical Journal*. 67, 6

**Acute Changes in Plasma Glucose Have Impact on Left Ventricular Systolic Function in Insulin-Treated Patients with Type 2 Diabetes**

Andersen, A., Jørgensen, P. G., Bagger, J. I., S., Baldassarre, M. P. A., Christensen, M. B., Abelin, K. U., Pedersen-Bjergaard, U., Holst, J. J., Lindhardt, T. B., Knop, F. K. & Vilsbøll, T., Jun 2020.

**Counterregulatory Responses to Hypoglycemia in Totally Pancreatectomized Patients**

Baekdal, M., Lund, A. B., Baldassarre, M. P. A., Egholm, J. I., Rose, K., Hansen, C., Storkholm, J. H., Christensen, M. B., Hartmann, B., Faber, J., Holst, J. J., Vilsbøll, T. & Knop, F. K., Jun 2020.

**Six-Day Subcutaneous GIP Infusion Increases Glycemic Time-in-Range in Patients with Type 1 Diabetes**

Heimbürger, S. M. N., Hoe, B., Nielsen, C. N., Bergmann, N. C., Hartmann, B., Holst, J. J., Storling, J., Vilsbøll, T., Dejgaard, T. F., Christensen, M. B. & Knop, F. K., Jun 2020.

**The Effect of GIP on Plasma Glucose in a Setting of Prandial Insulin Overdose and Physical Activity after Meal Intake in Patients with Type 1 Diabetes**

Hoe, B., Heimbürger, S. M. N., Gasbjerg, L. S., Lynggaard, M. B., Hartmann, B., Holst, J. J., Vilsbøll, T., Lund, A., Engberg, S., Dejgaard, T. F., Christensen, M. B. & Knop, F. K., Jun 2020.

**Clinical pharmacology of imeglimin for the treatment of type 2 diabetes**

Johansson, K. S., Brønden, A., Knop, F. K. & Christensen, M. B., 23 May 2020, In: Expert Opinion on Pharmacotherapy. 21, 8, p. 871-882 12 p.

**Glucose-dependent insulinotropic polypeptide is a pancreatic polypeptide secretagogue in humans**

Veedfald, S., Vedtofte, L., Skov-Jepesen, K., Deacon, C. F., Hartmann, B., Vilsbøll, T., Knop, F. K., Christensen, M. B. & Holst, J. J., 1 Mar 2020, In: The Journal of clinical endocrinology and metabolism. 105, 3, p. E502-E510 dgz097.

**Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists**

Gasbjerg, L. S., Bergmann, N. C., Stensen, S., Christensen, M. B., Rosenkilde, M. M., Holst, J. J., Nauck, M. & Knop, F. K., Mar 2020, In: Peptides. 125, 170183.

**GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals**

Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., Christensen, M. B., Vilsbøll, T., Holst, J. J., Rosenkilde, M. M. & Knop, F. K., Mar 2020, In: The Journal of clinical endocrinology and metabolism. 105, 3, p. E725-E738 dgz175.

**GIP and the gut-bone axis - physiological, pathophysiological and potential therapeutic implications**

Stensen, S., Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Christensen, M. B. & Knop, F. K., Mar 2020, In: Peptides. 170197.

**GIP's involvement in the pathophysiology of type 2 diabetes**

Christensen, M. B., Gasbjerg, L. S., Heimbürger, S. M., Stensen, S., Vilsbøll, T. & Knop, F. K., Mar 2020, In: Peptides. 125, 170178.

**Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease**

Heimbürger, S. M., Bergmann, N. C., Augustin, R., Gasbjerg, L. S., Christensen, M. B. & Knop, F. K., Mar 2020, In: Peptides. 125, 170174.

**No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes**

Bergmann, N. C., Gasbjerg, L. S., Heimbürger, S. M., Krogh, L. S. L., Dela, F., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., Vilsbøll, T., Lund, A. & Knop, F. K., Mar 2020, In: Diabetes Care. 43, 3, p. 588-596 9 p., dc190578.

**GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH<sub>2</sub>**

Gasbjerg, L. S., Hartmann, B., Christensen, M. B., Lanng, A. R., Vilsbøll, T., Jørgensen, N. R., Holst, J. J., Rosenkilde, M. M. & Knop, F. K., 1 Jan 2020, In: Bone. 130, 115079.

**Analgesics use and withdrawal in people with dementia - a register-based Danish study and a systematic review**

Sørensen, A. M. S., Tarp, S., Johannsen, P., Lolk, A., Bandak, E., Pedersen, H., Saxtrup, N., Kallehauge, H., Solem, E. J. & Christensen, M. B., Dec 2019, In: Danish Medical Journal. 66, 12, p. A5578

**The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion - A Review**

Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, M. B., Vilsbøll, T. & Knop, F. K., 22 Aug 2019, In: International Journal of Molecular Sciences. 20, 17, 4092.

**Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men without Diabetes**  
Bergmann, N. C., Lund, A., Gasbjerg, L. S., Jørgensen, N. R., Jessen, L., Hartmann, B., Holst, J. J., Christensen, M. B., Vilsbøll, T. & Knop, F. K., Jul 2019, In: The Journal of clinical endocrinology and metabolism. 104, 7, p. 2953-2960 8 p.

**Do callers to out-of-hours care misuse an option to jump the phone queue?**

Ebert, J. F., Huibers, L., Christensen, B., Lippert, F. K. & Christensen, M. B., Jun 2019, In: Scandinavian Journal of Primary Health Care. 37, 2, p. 207-217 11 p.

**Separate and Combined Gluco-Metabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 in Healthy Individuals**

Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., Veedefald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., Christensen, M. B., Vilsbøll, T., Holst, J. J., Rosenkilde, M. M. & Knop, F. K., May 2019, In: Diabetes. 68, 5, p. 906-917 12 p.

**Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study**

Bergmann, N. C., Lund, A., Gasbjerg, L. S., Meessen, E. C. E., Andersen, M. M., Bergmann, S., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., Vilsbøll, T. & Knop, F. K., 1 Apr 2019, In: Diabetologia. 62, 4, p. 665-675 11 p.

**Long term treatment with stimulant laxatives - clinical evidence for effectiveness and safety?**

Noergaard, M., Traerup Andersen, J., Jimenez-Solem, E. & Bring Christensen, M., 31 Jan 2019, In: Scandinavian Journal of Gastroenterology. 54, 1, p. 27-34 8 p.

**Two-bag intravenous N-acetylcysteine, antihistamine pretreatment and high plasma paracetamol levels are associated with a lower incidence of anaphylactoid reactions to N-acetylcysteine**

Daoud, A., Dalhoff, K. P., Christensen, M. B., Bøgevig, S. & Petersen, T. S., 2019, In: Clinical toxicology (Philadelphia, Pa.). p. 698-704 7 p.

**Ventrikelaspiration er meget sjældent indiceret ved forgiftninger**

Bøgevig, S., Christensen, M. B., Petersen, J. A., Dalhoff, K. P., Petersen, T. S., Palmqvist, D. F. & Groth Høgberg, L. C., 3 Dec 2018, In: Ugeskrift for Laeger. 180, 49

**Response to: Letter to the Editor: Hemodynamic Effects of Glucagon - A literature Review**

Meidahl Petersen, K., Bøgevig, S., Holst, J. J., Knop, F. K. & Christensen, M. B., 1 Dec 2018, In: The Journal of clinical endocrinology and metabolism. 103, 12, p. 4480-4481 2 p.

**Polypharmacy and medication deprescribing: A survey among multimorbid older adults in Denmark**

Schiøtz, M. L., Frølich, A., Jensen, A. K., Reuther, L., Perrild, H., Petersen, T. S., Kornholt, J. & Christensen, M. B., Dec 2018, In: Pharmacology Research & Perspectives. 6, 6, p. e00431

**Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects**

Demant, M., Bagger, J. I., Suppli, M. P., Lund, A., Gyldenløve, M., Hansen, K. B., Hare, K. J., Christensen, M., Sonne, D. P., Holst, J. J., Vilsbøll, T. & Knop, F. K., 28 Nov 2018, In: Metabolic Syndrome and Related Disorders. 16, 10, p. 530-536 6 p.

**Effects of high-dose, intravenous lipid emulsion on laboratory tests in humans: a randomized, placebo-controlled, double-blind, clinical crossover trial**

Petersen, K. M., Jørgensen, N. R., Bøgevig, S., Petersen, T. S., Jensen, T. B., Dalhoff, K. P. & Christensen, M. B., 27 Nov 2018, In: Clinical Chemistry and Laboratory Medicine. 56, 12, p. 2047-2057 11 p.

**Outcomes following calcium channel blocker exposures reported to a poison information center**

Christensen, M. B., Petersen, K. M., Bøgevig, S., Al-Gibouri, S., Jimenez-Solem, E., Dalhoff, K. P., Petersen, T. S. & Andersen, J. T., 27 Nov 2018, In: BMC pharmacology & toxicology. 19, 1, p. 78

**Hemodynamic effects of intravenous, high-dose lipid emulsion with and without metoprolol infusion in healthy volunteers: a randomized clinical trial**

Meidahl Petersen, K., Bøgevig, S., Petersen, T. S., Jensen, T. B., Dalhoff, K. P., Henriksen, T., Poulsen, H. E. & Christensen, M. B., 9 Nov 2018, In: *Clinical Pharmacology and Therapeutics*.

**Mono- and co-activation of the GIP and GLP-1 receptors inhibits bone resorption**

Bergmann, N., Lund, A., Heimbürger, S. M., Gasbjerg, L. S., Jørgensen, N. R., Jessen, L., Hartmann, B., Holst, J. J., Christensen, M., Vilsbøll, T. & Knop, F. K., 1 Oct 2018, In: *Diabetologia*. 61, suppl 1, p. S348-S348 1 p., 717.

**Postprandial effects of individual and combined GIP and GLP-1 receptor antagonism in healthy subjects**

Gasbjerg, L. S., Helsted, M. M., Sparre-Ulrich, A. H., Lanng, A. R., Stensen, S., Jakobsen, M. H., Hartmann, B., Christensen, M., Holst, J. J., Vilsbøll, T., Rosenkilde, M. M. & Knop, F. K., 1 Oct 2018, In: *Diabetologia*. 61, suppl 1, p. S246-S246 1 p., 503.

**The role of the incretins in the postprandial bone remodelling**

Helsted, M. M., Gasbjerg, L. S., Lanng, A. R., Stensen, S., Hartmann, B., Christensen, M., Holst, J. J., Vilsbøll, T., Rosenkilde, M. & Knop, F. K., 1 Oct 2018, In: *Diabetologia*. 61, Suppl 1, p. S221-S221 1 p., 449.

**Preclinical discovery and development of colesevelam for the treatment of type 2 diabetes**

Nerild, H. H., Christensen, M. B., Knop, F. K. & Brønden, A., Oct 2018, In: *Expert Opinion on Drug Discovery*. 13, 12, p. 1161-1167 8 p.

**General Practitioners' Barriers Toward Medication Reviews in Polymedicated Multimorbid Patients: How can a Focus on the Pharmacotherapy in an Outpatient Clinic Support GPs?**

Laursen, J., Kornholt, J., Betzer, C., Petersen, T. S. & Christensen, M. B., 25 Sept 2018, In: *Health services research and managerial epidemiology*. 5, p. 2333392818792169

**Cardiovascular effects of antidiabetic drugs**

Sørensen, A. M. & Christensen, M. B., Sept 2018, In: *Drugs of Today*. 54, 9, p. 547-559 13 p.

**Effect of a medicines management model on medication-related readmissions in older patients admitted to a medical acute admission unit-A randomized controlled trial**

Graabaek, T., Hedegaard, U., Christensen, M. B., Clemmensen, M. H., Knudsen, T. & Aagaard, L., 7 Aug 2018, In: *Journal of Evaluation in Clinical Practice*.

**A Systematic Review on Insulin Overdose Cases: Clinical Course, Complications and Novel Treatment Options**

Johansen, N. J. & Christensen, M. B., Jun 2018, In: *Basic & clinical pharmacology & toxicology*. 122, 6, p. 650-659 9 p.

**Hemodynamic Effects of Glucagon - A Literature Review**

Meidahl Petersen, K., Bøgevig, S., Holst, J. J., Knop, F. K. & Christensen, M. B., 1 May 2018, In: *The Journal of clinical endocrinology and metabolism*. 103, 5, p. 1804-1812 8 p.

**GIP(3-30)NH<sub>2</sub> is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study**

Gasbjerg, L. S., Christensen, M. B., Hartmann, B., Lanng, A. R., Sparre-Ulrich, A. H., Gabe, M. B. N., Dela, F., Vilsbøll, T., Holst, J. J., Rosenkilde, M. M. & Knop, F. K., Feb 2018, In: *Diabetologia*. 61, 2, p. 413-423 10 p.

**Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents**

Gasbjerg, L. S., Gabe, M. B. N., Hartmann, B., Christensen, M. B., Knop, F. K., Holst, J. J. & Rosenkilde, M. M., Feb 2018, In: *Peptides*. 100, p. 173-181 9 p.

**Important Aspects of Pharmacist-led Medication Reviews in an Acute Medical Ward**

Bülow, C., Faerch, K. U., Armandi, H., Jensen, B. N., Sonne, J., Christensen, H. R. & Christensen, M. B., Feb 2018, In: *Basic & clinical pharmacology & toxicology*. 122, 2, p. 253-261 9 p.

**Overdoses with Aripiprazole: Signs, Symptoms and Outcome in 239 Exposures Reported to the Danish Poison Information Centre**

Christensen, A. P., Boegevig, S., Christensen, M. B., Petersen, K. M., Dalhoff, K. P. & Petersen, T. S., Feb 2018, In: Basic & clinical pharmacology & toxicology. 122, 2, p. 293-298 6 p.

**Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption independently of Insulin and Glycemia**

Christensen, M. B., Lund, A., Calanna, S., Jørgensen, N. R., Holst, J. J., Vilsbøll, T. & Knop, F. K., 2018, In: The Journal of clinical endocrinology and metabolism. 103, 1, p. 288-294 7 p.

**Quality of care for people with multimorbidity - a case series**

Schiøtz, M. L., Høst, D., Christensen, M. B., Domínguez, H., Hamid, Y., Almind, M., Sørensen, K. L., Saxild, T., Holm, R. H. & Frølich, A., 18 Nov 2017, In: BMC Health Services Research. 17, 1, p. 745

**GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans**

Gasbjerg, L. S., Lanng, A. R., Hartmann, B., Sparre-Ulrich, A. H., Dela, F., Christensen, M., Holst, J. J., Vilsbøll, T., Rosenkilde, M. & Knop, F. K., 14 Sept 2017. 1 p.

**Increased liver fat content in totally pancreatectomised patients**

Bagger, J. I., Lund, A., Albrechtsen, N. J. W., Christensen, M., Grøndahl, M., Hansen, C. P., Storkholm, J. H., Holst, J. J., Vilsbøll, T. & Knop, F. K., 14 Sept 2017.

**The effects of GIP/GLP-1 receptor co-activation on appetite and food intake in overweight/obese subjects**

Bergmann, N., Lund, A., Gasbjerg, L. S., Meessen, E. C. E., Christensen, M., Vilsbøll, T. & Knop, F. K., 12 Sept 2017. 1 p.

**Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide**

Brønden, A., Knop, F. K. & Christensen, M. B., Jul 2017, In: Clinical Pharmacokinetics. 56, 7, p. 719-731 13 p.

**The immunoglobulin superfamily member CD200R identifies cells involved in type 2 immune responses**

Blom, L. H., Martel, B. C., Larsen, L. F., Hansen, C. V., Christensen, M. P., Juel-Berg, N., Litman, T. & Poulsen, L. K., Jul 2017, In: Allergy. 72, 7, p. 1081-1090 10 p.

**An adverse drug event manager facilitates spontaneous reporting of adverse drug reactions**

Vinther, S., Klarskov, P., Borgeskov, H., Darsø, P., Christophersen, A. K., Borck, B., Christensen, C., Hansen, M. V., Halladin, N. M. L., Christensen, M. B., Harboe, K. M., Lund, M. & Jimenez-Solem, E., Jan 2017, In: Danish Medical Bulletin (Online). 64, 1, p. A5315

**Non-Insulin Parenteral Therapies**

Vilsbøll, T., Christensen, M. & Knop, F. K., 2017, *Textbook of Diabetes*. p. 453

**Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis**

Andersen, S. E. & Christensen, M., Nov 2016, In: British Journal of Clinical Pharmacology. 82, 5, p. 1291-1302 12 p.

**Higher Endogenous Glucose Production during OGTT vs Isoglycemic Intravenous Glucose Infusion**

Lund, A., Bagger, J. I., Christensen, M., Grøndahl, M., van Hall, G., Holst, J. J., Vilsbøll, T. & Knop, F. K., 17 Aug 2016, In: Journal of Clinical Endocrinology and Metabolism. 101, 11, p. 4377-4384

**Erratum. Evidence of Extrapancreatic Glucagon Secretion in Man. Diabetes 2016;65:585-597**

Lund, A., Bagger, J. I., Wewer Albrechtsen, N. J., Christensen, M., Grøndahl, M., Hartmann, B., Mathiesen, E. R., Hansen, C. P., Storkholm, J. H., van Hall, G., Rehfeld, J. F., Hornburg, D., Meissner, F., Mann, M., Larsen, S., Holst, J. J., Vilsbøll, T. & Knop, F. K., Jun 2016

**Cholecystokinin-Induced Gallbladder Emptying and Metformin Elicit Additive Glucagon-Like Peptide-1 Responses**

Sonne, D. P., Rohde, U., Christensen, M., Hansen, M., Brønden, A., Toräng, S., Rehfeld, J. F., Holst, J. J., Vilsbøll, T. & Knop, F. K., May 2016, In: Journal of Clinical Endocrinology and Metabolism. 101, 5, p. 2076-83 8 p.

**Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans**

Christensen, M. B., Apr 2016, In: Danish Medical Bulletin (Online). 63, 4, 19 p., B5230.

**Searching for the physiological role of glucose-dependent insulinotropic polypeptide**

Holst, J. J., Windeløv, J. A., Boer, G. A., Pedersen, J., Svendsen, B., Christensen, M., Torekov, S., Asmar, M., Hartmann, B. & Nissen, A., Apr 2016, In: Journal of Diabetes Investigation. 7 Suppl 1, p. 8-12 5 p.

**Medication review in hospitalised patients to reduce morbidity and mortality**

Christensen, M. & Lundh, A., 20 Feb 2016, In: Cochrane Database of Systematic Reviews. 2, p. CD008986 84 p.

**Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors**

Sparre-Ulrich, A. H., Hansen, L. S., Svendsen, B., Christensen, M., Knop, F. K., Hartmann, B., Holst, J. J. & Rosenkilde, M. M., Jan 2016, In: British Journal of Pharmacology. 173, 1, p. 27-38 12 p.

**Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis**

Storgaard, H., Gluud, L. L., Bennett, C., Grøndahl, M. F., Christensen, M. B., Knop, F. K. & Vilsbøll, T., 2016, In: P L o S One. 11, 11, p. e0166125

**N- and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor**

Hansen, L. S., Sparre-Ulrich, A. H., Christensen, M., Knop, F. K., Hartmann, B., Holst, J. J. & Rosenkilde, M. M., 2016, In: British Journal of Pharmacology. 173, 5, p. 826-38

**Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes**

Christensen, M., Sparre-Ulrich, A. H., Hartmann, B., Grevstad, U., Rosenkilde, M. M., Holst, J. J., Vilsbøll, T. & Knop, F. K., Nov 2015, In: International journal of obesity (2005). 39, 11, p. 1651-4 4 p.

**Behandling af håndledsbrud hos ældre**

Christensen, M., Troelsen, A., Kold, S., Brix, M. & Ban, I., 17 Aug 2015, In: Ugeskrift for Laeger. 177, 34

**Laktoseholdige lægemidler kan som hovedregel indtages af personer med laktoseintolerans**

Vinther, S., Rumessen, J. J. & Christensen, M., 9 Mar 2015, In: Ugeskrift for Laeger. 177, V11140608, p. 2-5 4 p.

**Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy**

Brønden, A., Naver, S. V., Knop, F. K. & Christensen, M., 2015, In: Expert Opinion on Drug Metabolism & Toxicology. 11, 9, p. 1493-503 11 p.

**Glucose-Dependent Insulinotropic Polypeptide Augments Glucagon Responses to Hypoglycemia in Type 1 Diabetes**

Christensen, M., Calanna, S., Sparre-Ulrich, A. H., Kristensen, P. L., Rosenkilde, M. M., Faber, J., Purrello, F., van Hall, G., Holst, J. J., Vilsbøll, T. & Knop, F. K., 2015, In: Diabetes. 64, 1, p. 72-78

**Glucagon and type 2 diabetes: the return of the alpha cell**

Lund, A., Bagger, J. I., Christensen, M., Knop, F. K. & Vilsbøll, T., Dec 2014, In: Current Diabetes Reports. 14, 12, p. 555

**Glucose-dependent Insulinotropic Polypeptide Inhibits Bone Resorption in Humans**

Nissen, A. G. B., Christensen, M., Knop, F. K., Vilsbøll, T., Holst, J. J. & Hartmann, B., 21 Aug 2014, In: The Journal of clinical endocrinology and metabolism. p. jc20142547

**The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus**

Christensen, M., Miossec, P., Larsen, B. D., Werner, U. & Knop, F. K., 14 Aug 2014, In: Expert Opinion on Drug Discovery. p. 1-29 29 p.

**Elimination and Degradation of Glucagon-like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide in Patients with End-Stage Renal Disease**

Idorn, T., Knop, F. K., Jørgensen, M. B., Christensen, M., Holst, J. J., Hornum, M. & Feldt-Rasmussen, B., Jul 2014, In: The Journal of clinical endocrinology and metabolism. 99, 7, p. 2457-66 10 p.

**Glucose-dependent insulinotropic polypeptide (GIP): Effects on insulin and glucagon secretion in humans**

Christensen, M., 3 Apr 2014

**Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in human**

Bak, M. J., Wewer Albrechtsen, N. J., Pedersen, J. H., Hartmann, B., Christensen, M., Vilsbøll, T., Knop, F. K., Deacon, C. F., Dragsted, L. O. & Holst, J. J., Apr 2014, In: European journal of endocrinology / European Federation of Endocrine Societies. 170, 4, p. 529-538

**Adverse effects associated with high-dose olanzapine therapy in patients admitted to inpatient psychiatric care**

Petersen, A. B., Andersen, S. E., Christensen, M. & Larsen, H. L., Jan 2014, In: Clinical toxicology (Philadelphia, Pa.). 52, 1, p. 39-43 5 p.

**Ensembl Genomes 2013: scaling up access to genome-wide data**

Kersey, P. J., Allen, J. E., Christensen, M., Davis, P., Falin, L. J., Grabmueller, C., Hughes, D. S. T., Humphrey, J., Kerhornou, A., Khobova, J., Langridge, N., McDowall, M. D., Maheswari, U., Maslen, G., Nuhn, M., Ong, C. K., Paulini, M., Pedro, H., Toneva, I. & Tuli, M. A. & 13 others, Walts, B., Williams, G., Wilson, D., Youens-Clark, K., Monaco, M. K., Stein, J., Wei, X., Ware, D., Bolser, D. M., Howe, K. L., Kulesha, E., Lawson, D. & Staines, D. M., Jan 2014, In: Nucleic Acids Research. 42, Database issue, p. D546-52

**The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials**

Storgaard, H., Gluud, L. L., Christensen, M., Knop, F. K. & Vilsbøll, T., 2014, In: B M J Open. 4, 8, p. e005378

**Glucose-dependent Insulinotropic Polypeptide: Blood Glucose Stabilizing Effects in Patients with Type 2 diabetes**

Christensen, M., Calanna, S., Holst, J. J., Vilsbøll, T. & Knop, F. K., 10 Dec 2013, In: The Journal of clinical endocrinology and metabolism. p. jc20133644

**Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies**

Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T. & Knop, F. K., Oct 2013, In: Diabetes Care. 36, 10, p. 3346-52 7 p.

**Lixisenatide for the treatment of type 2 diabetes**

Brønden, A., Knop, F. K. & Christensen, M. B., Sept 2013, In: Drugs of Today. 49, 9, p. 537-53 17 p.

**GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations: pharmacokinetic and toxicological considerations**

Jespersen, M. J., Knop, F. K. & Christensen, M., Jan 2013, In: Expert Opinion on Drug Metabolism & Toxicology. 9, 1, p. 17-29 13 p.

**Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus**

Petersen, A. B. & Christensen, M., 2013, In: Diabetes, Metabolic Syndrome and Obesity. 6, p. 217-31 15 p.

**Medication review in hospitalised patients to reduce morbidity and mortality**

Christensen, M. & Lundh, A., 2013, In: Cochrane Database of Systematic Reviews. 2, p. CD008986

**Region bruger medicingennemgange trods svag evidens**

Lundh, A. & Christensen, M., 2013, In: Ugeskrift for læger. 175, p. 2741

**Diabetes. Add-on to metformin in T2DM--linagliptin or glimepiride?**

Christensen, M. & Knop, F. K., Oct 2012, In: Nature Reviews Endocrinology. 8, 10, p. 576-8 3 p.

**Comment on: Gögebakan et al. Glucose-dependent insulinotropic polypeptide reduces fat-specific expression and activity of 11 $\beta$ -hydroxysteroid dehydrogenase type 1 and inhibits release of free fatty acids. Diabetes 2012;61:292-300**

Knop, F. K. & Christensen, M., Sept 2012, In: Diabetes. 61, 9, p. e12

**Glukagonlignende peptid 1-analoger i behandlingen af type 2-diabetes mellitus**

Christensen, M., Vilsbøll, T. & Knop, F. K., 20 Aug 2012, In: Ugeskrift for Laeger. 174, 34, p. 1935; discussion 1935

**The unobtainable placebo: control of independent clinical research by industry?**

Christensen, M. & Knop, F. K., 7 Jan 2012, In: Lancet. 379, 9810, p. 30

**Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials**

Vilsbøll, T., Christensen, M., Junker, A. E., Knop, F. K. & Gluud, L. L., 2012, In: B M J. 344, p. d7771

**Regulation of glucagon secretion by incretins**

Holst, J. J., Christensen, M., Lund, A., De Heer, J. J. N., Svendsen, B. M., Kielgast, U. & Knop, F. K., Oct 2011, In: Diabetes, Obesity and Metabolism Online. 13 Suppl 1, p. 89-94 6 p.

**Lixisenatide for type 2 diabetes mellitus**

Christensen, M., Knop, F. K., Vilsbøll, T. & Holst, J. J., 1 Apr 2011, In: Expert Opinion on Investigational Drugs. 20, 4, p. 549-57 9 p.

**Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans**

Christensen, M., Vedtofte, L., Holst, J. J., Vilsbøll, T. & Knop, F. K., 2011, In: Diabetes. 60, 12, p. 3103-9 7 p.

**International or national publication of case reports**

Lundh, A., Christensen, M. & Jørgensen, A. W., 2011, In: Danish Medical Bulletin. 58, 2, p. A4242

**Malokoplaki i colon behandlet med sulfamethizol og trimetoprim**

Christensen, M., Knuhtsen, S. & Knudsen, E., 2011, In: Ugeskrift for Laeger. 173, 7, p. 509-10 2 p.

**The alpha-cell as target for type 2 diabetes therapy**

Christensen, M., Bagger, J. I., Vilsbøll, T. & Knop, F. K., 2011, In: Review of Diabetic Studies. 8, 3, p. 369-81 13 p.

**Therapy for obesity based on gastrointestinal hormones**

Bagger, J. I., Christensen, M., Knop, F. K. & Vilsbøll, T., 2011, In: Review of Diabetic Studies. 8, 3, p. 339-47 9 p.

**Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes**

Jimenez-Solem, E., Rasmussen, M. H., Christensen, M. & Knop, F. K., 1 Dec 2010, In: Current Opinion in Molecular Therapeutics. 12, 6, p. 790-7 8 p.

**Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes**

Christensen, M., Knop, F. K., Vilsbøll, T., Aaboe, K., Holst, J. J., Madsbad, S. & Krarup, T., 9 Aug 2010, In: Regulatory Peptides. 163, 1-3, p. 96-101 6 p.

**Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?**

Christensen, M. & Knop, F. K., 1 Apr 2010, In: Current Diabetes Reports. 10, 2, p. 124-32 9 p.

**Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus**

Christensen, M., Knop, F. K., Holst, J. J. & Vilsbøll, T., 1 Aug 2009, In: IDrugs : the investigational drugs journal. 12, 8, p. 503-13 11 p.

**The hypothalamo-pituitary-adrenal axis in major affective disorder: a review**

Christensen, M. V. & Kessing, L. V., 2001, In: Nordic Journal of Psychiatry. 55, 5, p. 359-63 5 p.